Self-Administered Parenteral Market Outlook 2024-2033: Trends and Projections
Self-Administered Parenteral Market, 2024 report by The Business Research Company offers comprehensive insights into the current state of the market and highlights future growth opportunities.
Market Size -
The self-administered parenteral market size has grown strongly in recent years. It will grow from $23.14 billion in 2023 to $24.57 billion in 2024 at a compound annual growth rate (CAGR) of 6.1%. The growth in the historic period can be attributed to rise in chronic diseases, aging population, government initiatives, patient education and support programs, the rising incidences of bone disorders.
The self-administered parenteral market size is expected to see steady growth in the next few years. It will grow to $29.8 billion in 2028 at a compound annual growth rate (CAGR) of 4.9%. The growth in the forecast period can be attributed to increasing patient preference for home healthcare, telemedicine and remote patient monitoring, patient education and support initiatives, growing personalized medicine. Major trends in the forecast period include integration of digital health solutions, customized drug delivery systems, emergence of targeted therapies, advancements in biologics.
Order your report now for swift delivery @
https://www.thebusinessresearchcompany.com/report/self-administered-parenteral-global-market-report
Scope Of Self-Administered Parenteral Market
The Business Research Company's reports encompass a wide range of information, including:
1. Market Size (Historic and Forecast): Analysis of the market's historical performance and projections for future growth.
2. Drivers: Examination of the key factors propelling market growth.
3. Trends: Identification of emerging trends and patterns shaping the market landscape.
4. Key Segments: Breakdown of the market into its primary segments and their respective performance.
5. Focus Regions and Geographies: Insight into the most critical regions and geographical areas influencing the market.
6. Macro Economic Factors: Assessment of broader economic elements impacting the market.
Self-Administered Parenteral Market Overview
Market Drivers -
The growing incidence of chronic diseases is expected to propel the growth of the self-administered parenteral market going forward. Chronic diseases are long-lasting medical conditions that generally progress slowly over time and often require ongoing management and treatment. Self-administered parenteral products are used in the management of chronic diseases to manage treatment independently, which can significantly improve adherence compared to oral medication. For instance, in January 2023, according to the National Institutes of Health, a US-based government agency, among the population aged 50 or above, the number of people with at least one chronic disease is expected to increase by 99.5% from 71.522 million in 2020 to 142.66 million by 2050. Therefore, the growing incidence of chronic diseases is driving the growth of the self-administered parenteral market.
Market Trends -
Major companies operating in the self-administered parenteral market are focusing on developing innovative products, such as the UDENYCA autoinjector, to provide increased choice and control, ultimately making treatment more accessible to patients. An autoinjector is a medical device designed to deliver a single dose of a particular drug. It is an intuitive design with administration triggered immediately and reliably by push-on-skin activation. For instance, in May 2023, Coherus BioSciences Inc., a US-based biotech company, launched the UDENYCA autoinjector, a self-administered parenteral medication in the US. The UDENYCA Autoinjector is a single-dose, prefilled autoinjector that offers patients an additional administration option for pegfilgrastim. It is designed to be intuitive, with administration triggered by push-on-skin activation, allowing for reliable and immediate delivery of a full pegfilgrastim dose. Additionally, it offers several user-friendly features that promote successful delivery, including fast dosing, intuitive design, dual coverage, at-home and in-office use, and a reduction of febrile neutropenia risk.
The self-administered parenteral market covered in this report is segmented –
1) By Product: Pre-Filled Syringes, Autoinjectors, Pen Injectors, Other Products
2) By Usage: Disposable, Reusable
3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Home Healthcare Providers, Specialty Clinics, Other Distribution Channels
4) By Application: Cardiovascular Diseases, Diabetes, Osteoporosis, Pain Management, Hormone Replacement, Other Applications
Get an inside scoop of the self-administered parenteral market, Request now for Sample Report @
https://www.thebusinessresearchcompany.com/sample.aspx?id=13927&type=smp
Regional Insights -
North America was the largest region in the self-administered parenteral market in 2023. The regions covered in the self-administered parenteral market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Key Companies -
Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Sanofi S.A., AstraZeneca PLC, Roche Holding AG, Eli Lilly and Company, Novo Nordisk A/S, Becton, Dickinson and Company, Teva Pharmaceutical Industries Ltd., Mylan N.V., Terumo Corporation, Catalent Inc., Dexcom Inc., West Pharmaceutical Services Inc., Gerresheimer AG, Biocon Limited, Insulet Corporation, Halozyme Therapeutics Inc., Ypsomed AG, Antares Pharma Inc., SHL Medical AG, Owen Mumford Ltd., Novartis AG, Kaleo Inc., Haselmeier AG, Bespak (A Consort Medical Company), Senseonics Holdings Inc., ScPharmaceuticals Inc., Fresenius Kabi AG
Table of Contents
1. Executive Summary
2. Self-Administered Parenteral Market Report Structure
3. Self-Administered Parenteral Market Trends And Strategies
4. Self-Administered Parenteral Market – Macro Economic Scenario
5. Self-Administered Parenteral Market Size And Growth
…..
27. Self-Administered Parenteral Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Comments
Post a Comment